Good point. If as Eureka suggests (Alan Kohler is a shareholder) this is a timing issue with revenue skewed to the second half then this is an pop to buy.
Research and Dev Expenses and staff costs are good costs as they increase growth later, so i wouldn't penalise a company doing the right things to grow.
Similarly , when profits are down due to increased depreciation or marketing or advertising expenses , then this can be a good buying opp.
- Forums
- ASX - By Stock
- AZV
- Is Azure Hyped?
Is Azure Hyped?, page-22
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AZV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online